Literature DB >> 277230

Cytotoxic and radiosensitizing effects of hypoxic cell sensitizers on EMT6 mouse mammary tumour cells in vivo and in vitro.

S Rockwell.   

Abstract

The radiosensitizing activities and toxicities of misonidazole, metronidazole, 2-Methythio-3-nitropyrrole (3NPR), 2-amino-5-nitrothiazole (ANT) and 2,5-dinitroimidazole (KA121) were studied using EMT6 tumour cells and BALB/c KaRw mice. For 10(-4)M concentrations of the drugs, the DMF's for hypoxic cells were: Misonidazole, 1.6; 3NPR, 1.5, ANT, 1.5; KA121, 1.8. The OER was 3.2. In general, the drugs were toxic to hypoxic cells and were not toxic to aerobic cells at 10(-3)M for 24 h. The LD50's in BALB/c KaRw mice were: misonidazole, 1500 mg/kg; 3NPR, 350 mg/kg ANT, 420 mg/kg. In vivo, 1 mg/g misonidazole or metronidazole reduced the terminal slope of the tumour cell survival curve by a factor of 2.2 or 1.6 respectively.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277230      PMCID: PMC2149387     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  5 in total

1.  Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells.

Authors:  B A Moore; B Palcic; L D Skarsgard
Journal:  Radiat Res       Date:  1976-09       Impact factor: 2.841

2.  Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system.

Authors:  S Rockwell; R F Kallman
Journal:  Radiat Res       Date:  1973-02       Impact factor: 2.841

3.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.

Authors:  S C Rockwell; R F Kallman; L F Fajardo
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  In vivo testing of hypoxic radiosensitizers using the KHT murine tumour assayed by the lung-colony technique.

Authors:  A M Rauth; K Kaufman
Journal:  Br J Radiol       Date:  1975-03       Impact factor: 3.039

Review 5.  In vivo-in vitro tumor systems: new models for studing the response of tumours to therapy.

Authors:  S Rockwell
Journal:  Lab Anim Sci       Date:  1977-10
  5 in total
  8 in total

1.  Influence of scheduling on two-drug combinations of alkylating agents in vivo.

Authors:  B A Teicher; S A Holden; S M Jones; J P Eder; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Interaction of platinum complexes of thiazin and xanthene dyes with hyperthermia.

Authors:  T S Herman; B A Teicher; M R Pfeffer; V S Khandekar; E Alvarez Sotomayor
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors:  B A Teicher; S A Holden; V Khandakar; T S Herman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  CAI: effects on cytotoxic therapies in vitro and in vivo.

Authors:  B A Teicher; S A Holden; Y N Chen; G Ara; T T Korbut; D Northey
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Anti-tumor effects and tumor immunogenicity following IL2 or IL4 cytokine gene transfection of three mouse mammary tumors.

Authors:  Y L Matory; M Chen; P S Goedegebuure; T J Eberlein
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

6.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Authors:  E A Sotomayor; B A Teicher; G N Schwartz; S A Holden; K Menon; T S Herman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes.

Authors:  B A Teicher; L J Gunner; J A Roach
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.